Rapip Study: Clinical Trial on Remifentanyl for Analgesia and Sedation of Ventilated Neonates and Infants

Overview

It shall be investigated whether ventilated neonates and infants with a remifentanyl based analgesia and sedation can be extubated faster after discontinuation of the opioid infusion compared to neonates and infants with a fentanyl based analgesia and sedation.

Full Title of Study: “Prospective Randomized, Double-blinded Clinical Trial on Remifentanyl for Analgesia and Sedation of Ventilated Neonates and Infants”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: April 2010

Detailed Description

"Newborns (≥ 36 weeks of gestation) and young infants (≤ 60 days) with need of mechanical ventilation receive next to midazolam either remifentanyl or fentanyl for analgesia and sedation. The study medication will be started not later than 12 hours after intubation and the maximum application time is 96 hours. The opioid infusion rate is started with either 9µg/kg/h remifentanyl or 3µg/kg/h fentanyl and will be adapted according to a clinical sedation score (Hartwig- and Comfort score). The maximum infusion rate is 30µg/kg/h remifentanyl or 10µg/kg/h fentanyl.

To judge the efficacy of both opioids, we will evaluate the sedation scores every 6 hours and measure the skin conductance during a painful procedure (tracheal suctioning). Next to the adverse events we document different vital parameters like heart rate, blood pressure or oxygen saturation every 6 hours to estimate the safety of both opioids.

The midazolam plasma level will be determined immediately before termination of the opioid and midazolam infusion when the child is clinically judged to be ready for extubation. The child will be extubated as soon as it reaches a certain level in the sedation score and exhibits stable spontaneous breathing.

After extubation we will look in both treatment groups for the possible development of hyperalgesia by investigating the cutaneous flexor reflex with von Frey hairs. The trial ends for each patient 48 hours after extubation.

Interventions

  • Drug: Remifentanyl
    • Start dose:9 µg/kg/h Maximum dose: 30 µg/kg/h
  • Drug: Fentanyl
    • start dose: 3 µg/kg/h Maximum dose: 10 µg/kg/h

Arms, Groups and Cohorts

  • Active Comparator: 2
    • Fentanyl
  • Experimental: 1
    • Remifentanyl

Clinical Trial Outcome Measures

Primary Measures

  • Duration of the artificial ventilation after discontinuation of the opioid infusion
    • Time Frame: at time of extubation (expected to be within 48 hours following discontinuation of the opioid infusion)
    • Extubation time point after discontinuation of the opioid infusion. Start of opioid infusion at the latest 12 h after intubation. Maximum duration of the opioid infusion 96 h.

Secondary Measures

  • Efficacy of a remifentanyl based analgesia and sedation of mechanically ventilated newborns and infants
    • Time Frame: during opioid infusion
    • During the opioid infusion we perform a score based evaluation every 6 hours. Start of opioid infusion at the latest 12 h after intubation. Maximum duration of the opioid infusion 96 h.
  • Safety of a continuous application of remifentanyl
    • Time Frame: up to 30 days after extubation
  • Possible withdrawal symptoms on both treatment groups after extubation
    • Time Frame: up to 48 h after extubation
  • Discharge time from the PICU after discontinuation of the opioid infusion
    • Time Frame: at time of discharge from the PICU (average 2 d after start of study medication)

Participating in This Clinical Trial

Inclusion Criteria

  • Ventilated term newborns and infants ≤ 60 days
  • Expected time of artificial ventilation between 12 and 96 hours

Exclusion Criteria

  • Neuromuscular diseases
  • Drug abuse of the mother (exclusion criteria for newborns)
  • Known hypersensitivity to Ultiva® or Fentanyl-Janssen®
  • Missing informed consent of the parents
  • Participation in another clinical trial during the last 4 weeks before start of this trial

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: 60 Days

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Cologne
  • Collaborator
    • GlaxoSmithKline
  • Provider of Information About this Clinical Study
    • Prof. Dr. Bernhard Roth, Clinic for Paediatrics
  • Overall Official(s)
    • Bernhard Roth, Prof., Principal Investigator, Clinic for Paediatrics, University of Cologne

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.